ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.
It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).ĪLPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in person.įor more info, please contact Alpha Cognition Inc.Īlpha Cognition Inc. The festivities run from 8 AM PT - 5:30 PM PT on the 12th and 13th with a morning session on the 14th. The 2021 LD Micro Main Event will be held at the Luxe Sunset Bel-Air in Los Angeles from Tuesday, October 12th to Thursday, October 14th. Register to watch the virtual presentation here.